Concomitant use of carbamazepine and rifampin in a patient with mycobacterium avium complex and seizure disorder

Journal of Pharmacy Technology

Volumn 30, Issue 3, 2014, Pages 93-96

  Egelund, Eric F ^a   Mohamed, MohamedEslam F ^a   Fennelly, Kevin P ^a   Peloquin, Charles A ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Carbamazepine; Drug interaction; Mycobacterium avium complex; Rifampin; Therapeutic drug monitoring

Indexed keywords

AZITHROMYCIN; CARBAMAZEPINE; CLARITHROMYCIN; ETHAMBUTOL; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; RIFAMPICIN; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; BODY MASS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; LIVER FUNCTION TEST; LUNG INFECTION; MIDDLE AGED; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM INTRACELLULARE AVIUM; PULMONARY MYCOBACTERIUM AVIUM COMPLEX INFECTION; SEIZURE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; VITAL SIGN;

EID: 84902130274     PISSN: 87551225     EISSN: 15494810     Source Type: Journal    
DOI: 10.1177/8755122514523934     Document Type: Article

References (17)

1. Fleenor ME, Harden JW, Curtis G. Interaction between carbamazepine and antituberculosis agents. Chest. 1991;99:1554.
2. Valsalan VC, Cooper GL. Carbamazepine intoxication caused by interaction with isoniazid. Br Med J (Clin Res Ed). 1982;285:261-262.
3. Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. N Engl J Med. 1982;307:1325-1327. doi:10.1056/NEJM198211183072107.
4. Zolezzi M. Antituberculosis agents and carbamazepine. Am J Psychiatry. 2002;159:874.
5. Gelisse P, Hillaire-Buys D, Halaili E, et al. Carbamazepine and clarithromycin: a clinically relevant drug interaction. Rev Neurol (Paris). 2007;163:1096-1099.
6. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995;171:747-750. doi:10.1093/infdis/171.3.747.
7. Reitman ML, Chu X, Cai X, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234-242. doi:10.1038/clpt.2010.271.
8. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos. 2006;34: 1175-1181. doi:10.1124/dmd.105.009076.
9. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819-850. doi:10.2165/00003088-200342090-00003.
10. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther. 2005;78:154-167. doi:10.1016/j. clpt.2005.04.007.
11. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther. 2007;81: 194-204. doi:10.1038/sj.clpt.6100038.
12. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol. 2001;51:345-349. doi:10.1046/j.1365- 2125.2001.01359.x.
13. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007;52:333-346. doi:10.1016/j.neu ropharm.2006.07.038.
14. Li AP, Reith MK, Rasmussen A, et al. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin. Chem Biol Interact. 1997;107:17-30.
15. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis. 1999;28:419-429. doi:10.1086/515174.
16. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175:367-416. doi:10.1164/rccm.200604- 571ST.
17. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41:674-680. doi:10.1345/aph.1H423.